摘要
人角膜内皮细胞(HCECs)是一种有丝分裂后的单层内皮细胞,因此,其在体内和体外的增殖能力十分有限。HCECs在严重受损的情况下会发生内皮失代偿,极易引起失明。目前,唯一有效的治疗方法是使用含健康角膜内皮的供体植片进行角膜移植。因此,世界范围内供体材料的严重短缺推动了对角膜内皮替代来源的研究。随着HCECs的细胞培养研究的不断开展,细胞治疗为角膜内皮失代偿提供了希望。本文对角膜内皮细胞治疗方面的最新研究进展进行综述。
Human corneal endothelial cells(HCECs)are post-mitotic monolayer endothelial cells with restricted proliferative ability in vivo and in vitro.When HCECs are severely damaged,endothelial decompensation will occur,which can easily cause blindness.Currently,the only effective treatment is to transplant a donor cornea that contains a healthy corneal endothelium.However,there is a severe shortage of donor corneas worldwide,driving research into alternative sources of corneal endothelium(CE).The on-going research on HCECs culture has shown that it is possible to regenerate the damaged CE by cell therapy.This review aims to provide the latest advances in the CE cell therapy.
作者
胡芷馨
肖宇婷
刘欣
张明昌
HU Zhixin;XIAO Yuting;LIU Xin;ZHANG Mingchang(Department of Ophthalmology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei Province,China)
出处
《眼科新进展》
CAS
北大核心
2021年第11期1097-1100,共4页
Recent Advances in Ophthalmology
基金
科技部国家重点研发计划项目(编号2017YFE0103500)
中央高校基本科研业务费专项资金项目(编号2019kfyXMBZ065)。
关键词
角膜内皮
细胞治疗
角膜内皮细胞移植
再生
corneal endothelium
cell therapy
corneal endothelial cell transplantation
regeneration